Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-200M in Melanoma Brain Metastases

NCT05341349 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05341349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05341349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-200M in Melanoma Brain Metastases
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Terminated
Start date
October 13, 2022
Completion date
May 31, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, melanoma of unknown primary, metastatic malignant neoplasm in the brain, metastatic melanoma, metastatic mucosal melanoma, metastatic ocular melanoma, pathologic stage iv cutaneous melanoma ajcc v8